Alpha Cubed Investments LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 163,106 shares of the company’s stock after purchasing an additional 8,827 shares during the period. Johnson & Johnson accounts for about 2.3% of Alpha Cubed Investments LLC’s investment portfolio, making the stock its 8th biggest holding. Alpha Cubed Investments LLC’s holdings in Johnson & Johnson were worth $24,283,000 as of its most recent filing with the SEC.
Other large investors also recently added to or reduced their stakes in the company. Lake Point Wealth Management grew its holdings in Johnson & Johnson by 144.4% during the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after purchasing an additional 169 shares during the period. Islay Capital Management LLC bought a new stake in Johnson & Johnson during the second quarter valued at about $42,000. FAI Wealth Management grew its holdings in Johnson & Johnson by 45.9% during the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares during the period. SeaBridge Investment Advisors LLC grew its holdings in Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares during the period. Finally, Crewe Advisors LLC grew its holdings in Johnson & Johnson by 909.1% during the third quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after purchasing an additional 300 shares during the period. 67.44% of the stock is owned by institutional investors and hedge funds.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by insiders.
NYSE:JNJ opened at $148.10 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $389.92 billion, a P/E ratio of 23.29, a P/E/G ratio of 3.36 and a beta of 0.68. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The business’s 50-day moving average is $148.57 and its 200 day moving average is $146.59.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.22. The company had revenue of $21.08 billion for the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.12 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 8 earnings per share for the current year.
Several analysts have issued reports on JNJ shares. SVB Leerink reissued an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. Cantor Fitzgerald upped their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday. Bank of America reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the stock from $161.00 to $164.00 in a research note on Monday, July 20th. Finally, Credit Suisse Group upped their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Buy” and an average price target of $164.93.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More: Understanding Specialty Certificates of Deposit
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.